<DOC>
	<DOCNO>NCT02774278</DOCNO>
	<brief_summary>This study ass potentially predictive marker efficacy participant NSCLC receive oral erlotinib ( Tarceva ) therapy . The anticipated time study treatment disease progression , unacceptable toxicity death .</brief_summary>
	<brief_title>A Study Erlotinib ( Tarceva ) Participants With Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Advanced NSCLC Tumor accessible biopsy bronchoscopy Disease progression follow course standard chemotherapy , participant unwilling/unable undergo chemotherapy Unstable systemic disease Any malignancy last 5 year Brain metastases Previous treatment therapy act epidermal growth factor receptor ( EGFR ) axis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>